Iilun Murphy

Iilun Murphy, MD, serves as the director of the Office of Generic Drugs (OGD) in the Center for Drug Evaluation and Research (CDER).


FDA Offers GDUFA III Insight

The Generic Drug User Fee Amendments, designed to facilitate the delivery of safe and effective generic drugs to the public and improve the predictability of the ANDA assessment process, has undergone changes that will impact the pre-ANDA and ANDA approval process—and ultimately the path for generic drugs to approval.